UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
19.91
-0.55 (-2.69%)
At close: Mar 9, 2026, 4:00 PM EDT
19.80
-0.11 (-0.55%)
After-hours: Mar 9, 2026, 5:11 PM EDT
UroGen Pharma Employees
UroGen Pharma had 235 employees as of December 31, 2024. The number of employees increased by 34 or 16.92% compared to the previous year.
Employees
235
Change (1Y)
34
Growth (1Y)
16.92%
Revenue / Employee
$382,537
Profits / Employee
-$534,822
Market Cap
969.26M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| AbCellera Biologics | 596 |
| Pharming Group | 404 |
| Xeris Biopharma Holdings | 394 |
| Geron | 229 |
| Inhibrx Biosciences | 161 |
| Cullinan Therapeutics | 111 |
| ArriVent BioPharma | 52 |
| GH Research | 50 |
URGN News
- 3 days ago - UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 days ago - UroGen: ZUSDURI Poised To Replace TURBT Surgery As SOC In Certain Bladder Cancers - Seeking Alpha
- 7 days ago - UroGen Pharma Ltd. (URGN) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 7 days ago - UroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 7 days ago - UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors - GlobeNewsWire
- 10 days ago - ZUSDURI™ Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC - GlobeNewsWire
- 13 days ago - UroGen Pharma to Present at the TD Cowen 46th Annual Health Care Conference - GlobeNewsWire
- 14 days ago - UroGen Pharma to Report Fourth Quarter and Full-Year 2025 Financial Results on Monday, March 2, 2026 - GlobeNewsWire